title: Racial disparities in the treatment of advanced epithelial ovarian cancer.
abstract: OBJECTIVE
  To examine whether treatment with guideline-recommended care (surgery and chemotherapy) is associated with mortality differences between black and white women with advanced epithelial ovarian cancer.
  
  
  METHODS
  We conducted an observational cohort study using the Surveillance, Epidemiology, and End Results (SEER) linked to Medicare claims for 1995-2007. We evaluated long-term survival for 4,695 black and white women with stage III or stage IV epithelial ovarian cancer with Kaplan-Meier analysis and Cox regression, and then in patients matched by propensity score to create two similar cohorts for comparison. We investigated the association between race, stage, and survival among women who were treated with guideline-recommended care and those who received incomplete treatment.
  
  
  RESULTS
  Black women with advanced epithelial ovarian cancer were more likely to die than white women (unadjusted hazard ratio [HR] 1.27; 95% confidence interval [CI] 1.10-1.46). Black women were less likely than white women to receive guideline-recommended care (54% compared with 68%; P<.001), and women who did not receive recommended treatment had lower survival rates than women who received recommended care. Cox proportional hazards models demonstrated no differences in black women compared with white women regarding mortality among women who were treated with guideline-recommended care (adjusted HR 1.04; 95% CI 0.85-1.26), or among women who received incomplete treatment (adjusted HR 1.09; 95% CI 0.89-1.34). The survival analysis of patients matched by propensity score confirmed these analyses.
  
  
  CONCLUSIONS
  Differences in rates of treatment with guideline-recommended care are associated with black-white mortality disparities among women with advanced epithelial ovarian cancer.
  
  
  METHODS
  III.
authors.affiliation: Departments of Health Evidence & Policy, Obstetrics, Gynecology, and Reproductive Science, and Medicine, Mount Sinai School of Medicine, New York, New York.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Howell
authors.forename: Natalia
authors.initials: N
authors.lastname: Egorova
authors.forename: Monica P
authors.initials: MP
authors.lastname: Hayes
authors.forename: Juan
authors.initials: J
authors.lastname: Wisnivesky
authors.forename: Rebeca
authors.initials: R
authors.lastname: Franco
authors.forename: Nina
authors.initials: N
authors.lastname: Bickell
mesh_terms: D001741:Black or African American / Q000208:ethnology*; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D013509:Gynecologic Surgical Procedures; D054625:Healthcare Disparities / Q000208:ethnology*; D006801:Humans; D006278:Medicare / Q000706:statistics & numerical data; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000208:ethnology* / Q000401:mortality / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000208:ethnology* / Q000401:mortality / Q000628:therapy*; D017410:Practice Guidelines as Topic; D057216:Propensity Score; D018426:SEER Program; D015996:Survival Rate; D014481:United States / Q000453:epidemiology; D044465:White People / Q000208:ethnology*
chemical_list: D000970:Antineoplastic Agents